Bio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q1 2025 Earnings of $2.39 Per Share, Zacks Research Forecasts

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities researchers at Zacks Research raised their Q1 2025 EPS estimates for shares of Bio-Rad Laboratories in a research note issued to investors on Monday, April 15th. Zacks Research analyst R. Anand now forecasts that the medical research company will earn $2.39 per share for the quarter, up from their previous forecast of $2.35. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.41 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q3 2025 earnings at $3.83 EPS.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, February 15th. The medical research company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.17. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The firm had revenue of $681.18 million for the quarter, compared to analysts’ expectations of $685.00 million. During the same quarter in the prior year, the business earned $3.31 EPS. The business’s quarterly revenue was down 6.7% on a year-over-year basis.

Several other equities research analysts have also issued reports on BIO. UBS Group increased their target price on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Royal Bank of Canada reduced their target price on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a report on Friday, February 16th. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Finally, Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $400.00 to $365.00 in a report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $468.00.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO traded down $1.89 during trading on Wednesday, hitting $290.86. The company’s stock had a trading volume of 214,091 shares, compared to its average volume of 199,335. The company has a 50-day moving average of $332.35 and a 200-day moving average of $321.22. Bio-Rad Laboratories has a 12 month low of $261.59 and a 12 month high of $489.36. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the completion of the sale, the executive vice president now directly owns 6,942 shares of the company’s stock, valued at approximately $2,332,512. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 17.50% of the company’s stock.

Institutional Investors Weigh In On Bio-Rad Laboratories

A number of institutional investors have recently added to or reduced their stakes in BIO. Massachusetts Financial Services Co. MA purchased a new stake in Bio-Rad Laboratories during the 3rd quarter valued at approximately $116,036,000. Norges Bank purchased a new stake in Bio-Rad Laboratories during the 4th quarter valued at approximately $73,142,000. Parnassus Investments LLC purchased a new stake in Bio-Rad Laboratories during the 3rd quarter valued at approximately $79,143,000. Parsifal Capital Management LP bought a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at approximately $61,866,000. Finally, Deerfield Management Company L.P. Series C bought a new position in shares of Bio-Rad Laboratories during the 3rd quarter valued at approximately $62,351,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.